Video
Assessing Adverse Events From Investigational Dose of Semaglutide Injection for Type 2 Diabetes
Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, discusses the adverse events experienced by patients during the SUSTAIN FORTE phase 3 clinical trial evaluating an investigational 2 mg dose of semaglutide injection in adults with type 2 diabetes.
Pharmacy Times interviewed Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, on results from the SUSTAIN FORTE phase 3 clinical trial evaluating an investigational 2 mg dose of semaglutide (Ozempic; Novo Nordisk) injection in adults with type 2 diabetes.
During the discussion, Radin addresses what some of the adverse events experienced by patients with type 2 diabetes were during the trial, and how patients were able to handle them.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
